PTJ
MLYS icon

Paul Tudor Jones’s Mineralys Therapeutics MLYS Stock Holding History

Paul Tudor Jones’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9M Buy
738,370
+582,630
+374% +$16M 0.03% 488
2026
Q1 		$4.22M Buy
155,740
+116,694
+299% +$3.42M 0.01% 1276
2025
Q4 		$1.42M Buy
+39,046
New +$1.57M ﹤0.01% 2050

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Paul Tudor Jones's MLYS Position: Q2 2026 in Review

Paul Tudor Jones increased its Mineralys Therapeutics (MLYS) stake by 374% in Q2 2026, buying an estimated $16M and bringing the position to 738,370 shares worth $19.9M. The position accounts for 0.03% of the portfolio, ranked #488.

Paul Tudor Jones first reported a position in MLYS in Q4 2025 and has held it in 3 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Paul Tudor Jones held 738,370 shares of Mineralys Therapeutics worth $19.9M as of Q2 2026.
  • Paul Tudor Jones bought 582,630 Mineralys Therapeutics shares in Q2 2026, an estimated $16M.
  • Mineralys Therapeutics made up 0.03% of Paul Tudor Jones's portfolio in Q2 2026, its #488 holding.
  • Paul Tudor Jones first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.